Subscribe to our Newsletters !!
In molecular biology, the LAMP (Loop-Mediated Isot
Pharmaceutical laboratories have been adopting imm
Generally, a debate about Isopure protein and regu
Alembic Pharmaceuticals Limited appoints Mr. Manis
The importance of comparing the treatment of asthm
It is important to understand that natural remedie
In a world constantly in motion, Microbioz India r
The prevalence of fever and joint pain is so common of symptoms that it overlaps with almost any prevalent disease in the tropics and hence for the better part of the virulent pathway of CHIK virus in the body, the patients remain asymptomatic to the detection of Chikungunya, thereby making it more life-threatening and requiring immediate diagnosis and treatment. The timing and the epidemiology of Chikungunya has been so overlapping that it has always flourished under the wrath of Dengue significantly in the country. As per the published data, the last known epidemic of Chikungunya was recorded in 2016-17, recording the highest infection rate in modern times.
This time the challenges of detecting true Chikungunya patient with prevalence of Dengue and ongoing COVID pandemic is relatively higher with most of the symptoms common to the other viral diseases. Though mortality rate is rare in Chikungunya and in normal cases a past infection provides passive immunity, but if a patient develops a co-infection or a secondary infection after Dengue or COVID then the immune system which is already week or compromised can make it more serious requiring quick attention to life support systems. As of July 2020, NVBDCP which is the nodal agency appointed by Government for management of vector borne diseases in the country has reported the presence of 18533 suspected cases and 2812 confirmed cases.
While travelers who are normally at high risk of infection are under control due to limited movement in restrictions during the pandemic, the household mass has to always follow prevention methods like: prevent mosquito bites during daytime, thermal fogging, applying repellants based on Picaridin, disposal of stagnant water and use of mosquito nets.
Although there is no precise or preventive medication or vaccine against Chikungunya, the only way to deal with the threat is with early and proper detection followed by diagnosis of the virus. The most common and acceptable tests are the Rapid Diagnostic Card tests which are known for their quick results and ease of use with spontaneous reporting of results. The advent of ELISA has increased the specificity of the results to a higher level. Molecular Platforms like PCR and NAAT are required for cases with severe complications or co-infections.
J Mitra & Co. has been a pioneer in the field of diagnostics in the country and keeping the mantle high for Make In India has been providing affordable, user friendly, and quality products for detection of Chikungunya for the last 4 decades. The Chikungunya Rapid Test and ELISA kits are based on the detection of IgM antibodies thereby screening the patient at an early antibody response, giving ample time for the clinicians to decide a progressive treatment plan for the patients. High Quality, convenient pack size, higher shelf life and the evaluation from reputed institutions is a testament that the products are quite popular among the customers.
